ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / SCNX
PCSA (39) ADXN (48) LGVN (27) GELS (54) ⌘ Pro Terminal →

Scienture Holdings Inc. (SCNX) — RQD Stock Rating Cockpit

$3.23 +0.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.23

Scienture Holdings Inc. (SCNX) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $5.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SCNX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SCNX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Scienture Holdings Inc. (NASDAQ: SCNX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $3.23 (+0.31% 1D, market cap $5.3M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SCNX ranks #874 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SCNX compare to PCSA and ADXN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SCNX carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 76.8%, and ROIC of -35.0%. By comparison, PCSA (Processa Pharmaceuticals Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M) and ADXN (Addex Therapeutics Ltd) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $5.3M). Among the 5-stock peer group, SCNX leads on earnings multiple (N/A) while SCNX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SCNX?
▼

Per SCNX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001382574), Scienture Holdings Inc. generated $431.6K in revenue (+215.9% YoY), -$41.5M in net income, and -$13.4M in free cash flow against $84.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.23 (-0.13%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510028
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (5)Whales (3)SEC (8)Macro (7)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-13.6% Base Target
$29 Bull$3 Base$2 Bear
📬 FREE SCNX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SCNX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (28/100 Composite)
🔍 WHY SCNX SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (29% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (25% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 34.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
36
Grade E$3.24-5.9% Next Q
Q2 (-2Q)
33
Grade E$3.05+5.9% Next Q
Q3 (-1Q)
31
Grade E$3.23+0% Next Q
Current
28
Grade E$3.23-10% Hist 90D α
Trajectory: E (36) → E (28)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SCNX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SCNX currently carries a cautious 28/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.02) and Max Pain ($3.39) forces dealer call-delta covering toward $29.14.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SCNX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SCNX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 28%NO 72%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
34.630 Oversold · 70 Hot
ALTMAN-Z SHIELDDISTRESS RISK (<1.8)
0.20>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
4 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $3$3.23H: $28
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 15 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on SCNX

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (25)

-35.0% ROIC with 76.8% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (40)

Altman-Z 0.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (25)

8/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like SCNX
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SCNX)

  • ✓Walkthrough of SCNX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SCNX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -66.94%📐 HORIZONTAL RANGE
2026-11-03O $3.49H $3.49L $3.22C $3.23VOL 11.4K
RES: $12.22SUP: $2.27SMA50: $6.02SMA200: $9.09
$20.23$15.46$10.70$5.93$1.16RES $12.22SUP $2.27$3.232026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SCNX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SCNX Butterfly Map → + Track SCNX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +215.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SCNX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SCNX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SCNX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SCNX)

Health Care Rank #874 of 1015 ⚔️ PCSA vs SCNX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SCNX vs. PCSA, ADXN, LGVN, GELS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Scienture Holdings Inc. (SCNX) ranks #874 by composite RQD confidence (28/100, grade E) and #934 by equity capitalization ($5.3M). Within this direct 5-issuer industry benchmark cohort, SCNX leads on earnings valuation at N/A trailing P/E, while SCNX leads on capital efficiency and profitability with -35.0% ROIC and 76.8% gross margin. GELS currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with SCNX at 28/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SCNX ACTIVE
Scienture Holdings Inc.
E 28/100 — 76.8% -35.0% +0.31% $5.3M Benchmark Subject
PCSA
Processa Pharmaceuticals Inc.
D- 39/100 — — -35.0% -2.12% $5.3M /pcsa-vs-scnx →
ADXN
Addex Therapeutics Ltd
D 48/100 — — — -3.24% $5.3M /adxn-vs-scnx →
LGVN
Longeveron Inc. (Class A)
E 27/100 — 67.0% -35.0% +2.40% $5.3M /lgvn-vs-scnx →
GELS
Gelteq Limited
D+ 54/100 — — — -0.10% $5.2M /gels-vs-scnx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001382574 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Scienture Holdings Inc. (SCNX) reported GAAP revenue of $431.6K (+215.9% vs. FY2024 revenue of $136.6K , and -68.4% cumulative change since FY2023) , GAAP net income of -$41.5M, operating cash flow of -$13.4M, and free cash flow of -$13.4M (+6.3% YoY). On the balance sheet, SCNX closed FY2025 with $84.2M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $431.6K -$41.5M -$13.4M -$13.4M $84.2M —
FY2024 (FY) 2024-12-31 $136.6K $13.6M -$14.3M -$14.3M $104.9M —
FY2023 (FY) 2023-12-31 $1.4M -$17.8M -$2.2M -$2.2M — —

3. SCNX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SCNX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Scienture Holdings Inc. (NASDAQ: SCNX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $3.23 (+0.31% 1D, market cap $5.3M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SCNX ranks #874 in composite RQD confidence.

How does SCNX compare to PCSA and ADXN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SCNX carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 76.8%, and ROIC of -35.0%. By comparison, PCSA (Processa Pharmaceuticals Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M) and ADXN (Addex Therapeutics Ltd) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $5.3M). Among the 5-stock peer group, SCNX leads on earnings multiple (N/A) while SCNX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SCNX?

Per SCNX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001382574), Scienture Holdings Inc. generated $431.6K in revenue (+215.9% YoY), -$41.5M in net income, and -$13.4M in free cash flow against $84.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SCNX trading relative to its 50-day, 200-day, and 52-week technical levels?

SCNX last traded at $3.23 (+0.31% on volume of 6,146 shares), positioning the stock -46.35% below its 50-day simple moving average ($6.02) and -64.47% below its 200-day simple moving average ($9.09). Across its 52-week range of $2.64 to $27.75, SCNX sits at the 2.3% percentile with a 14-day RSI of 34.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.83 to $3.63).

Direct Sub-Reports: SCNX RQD Cockpit SCNX 12M Forecast SCNX Earnings & Move SCNX Dividends & DRIP SCNX Insiders & 13F SCNX Whale Options SCNX Profit Sankey SCNX News & Why
ROARABLE RATING BRIEF • RQD 28/100 (E) ✓ SEC XBRL & RQD VERIFIED

SCNX — Scienture Holdings Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Scienture Holdings Inc. (SCNX) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.23 (+0.31% 1D, market capitalization $5.3M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 76.8%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Scienture Holdings Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry (per the company profile). Reported gross margin is 76.8%, indicating that the company's cost of revenue is low relative to sales, though revenue is very small in absolute terms (per the market data and SEC financials). — beyond these sector and margin facts.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Scienture Holdings Inc. (SCNX) reported $431.6K in annual revenue (up from $136.6K in FY2024, +215.9% YoY) and -$41.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.4M revenue, -$17.8M net income) through FY2025, SCNX scaled operating cash flow to -$13.4M and free cash flow to -$13.4M, backed by $84.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 28/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.64 – $27.75 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies cannot be mapped from source data. A prospective investor should note that the absence of mapped links means no second-order ripples can be identified from the provided material.

  • Key Question #1: Can SCNX sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $431.6K and free cash flow of -$13.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SCNX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SCNX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Scienture Holdings Inc. (SCNX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SCNX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SCNX Bull vs. Bear Conversation Board — What's Your Call at $3.23?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SCNX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SCNX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $3.74 (+16.1%)
📌 Pinned Debate

Headlines report revenue soaring 256% and a Nasdaq compliance regain, with management targeting 2027 profitability.

Picked up a starter position in SCNX in my $100K Virtual Cash book at $3.22. Headlines report revenue soaring 256% and a Nasdaq compliance regain, with management targeting 2027 profitability.. Trading inside a $2.64–$27.75 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

VolSurface_Trader 🐂 BULL

@FadeTheHype Shorting a 3/20 institutional whale-flow stock at $3.22 is dangerous when funds are rotating into Health Care.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $2.54 (-21.1%)
Spot @ $3.22

Operating margin of -60% and ROIC of -35% alongside an Altman Z-Score of 0.2 signal severe cash burn and forensic balance sheet risk.

Operating margin of -60% and ROIC of -35% alongside an Altman Z-Score of 0.2 signal severe cash burn and forensic balance sheet risk.. Look at the math on SCNX: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $2.83 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%